Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Oral and Sublingual Ketamine in MDD
NCT07683988Phase 1Not yet recruiting
- Sponsor
- Western University
- Start
- Oct 2026
- Primary completion
- Aug 2027
01
Overview
Phase 1, randomised, single-blind trial of ketamine in major depressive disorder (MDD) (2 arms), sponsored by Western University. Primary endpoint: Pharmacokinetic measures at 8 hours. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07683988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07683988.